A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer - Kamaraju, Sailaja; Fowler, Amy M.; Tarima, Sergey; Chaudhary, Lubna N.; Burkard, Mark E.; Giever, Thomas; Cheng, Yee C.; Parkes, Amanda; Lange, Carol A.; Pipp-Dahm, Michele; Hegeman, Robert; Siddiqui, Nauman; et al. (Clinical breast cancer, 2025)
Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antiprogestins; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; CDK4/6 inhibitors; Female; Fulvestrant - administration & dosage; Fulvestrant - adverse effects; Hormone receptor positive; Humans; Metastatic breast cancer; Middle Aged; Novel treatments; Positron Emission Tomography Computed Tomography; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Antiprogestins; Novel treatments; Metastatic breast cancer; Hormone receptor positive; CDK4/6 inhibitors